http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-107345253-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-156 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-166 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-11 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-6886 |
| filingDate | 2017-07-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2020-12-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2020-12-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-107345253-B |
| titleOfInvention | Lung cancer clinical medication gene detection standard substance and application thereof |
| abstract | The invention discloses a clinical drug gene detection standard substance for lung cancer and application thereof. Wherein, the gene detection standard substance for clinical medicine for lung cancer comprises: the lowest detection limit reference product at least comprises two DNA mixtures with different grades of variation frequency, and each grade of DNA mixture with variation frequency comprises the following mutation sites: EGFR gene G719S, E746_ A750del, S768I, T790M, L858R mutation sites; EML4-ALK gene E6; e20 and E13; the E20 mutation site; SLC34A2-ROS1 gene E4; e32 mutation site. By applying the technical scheme of the invention, the fact that the kit can detect gene mutation and gene frequency can be judged according to the result, the accuracy of the detection result of the existing kit is verified, and more accurate guidance is provided for clinical medication. |
| priorityDate | 2017-07-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 20.